HEALTH CARE DECISION MAKERS OPEN FOR PUBLIC AND PATIENT INVOLVEMENT IN COVERAGE DECISIONS

Published Apr 10, 2015
Brussels, Belgium – In a democratic system, politicians are elected to make decisions regarding health care priorities. In deliberation-driven systems, such as in Belgium, coverage decisions are based on the outcomes of a deliberation amongst stakeholders (including public authorities, providers, academics, and sickness funds). Patients and citizens are rarely –if-ever- directly involved in this process. Should citizens and patients be involved more intensively? If so, how?  To find out, researchers from the Belgian Health Care Knowledge Centre (KCE) performed a two-round Delphi survey on Belgian stakeholders currently involved or not (yet) involved in the decision-making processes. Eighty people participated in both rounds. The Delphi panel of participants consisted of politicians on national, regional and local level, members of advisory committees, patient organisations, and consumer organisations. Panel participants preferred citizens and patients to be consulted within the existing structures and at particular milestones in the process. Justification should be provided when decisions deviate from the recommendation of the public or patients. The researchers feel that further research is needed regarding the effectiveness of public and patient involvement strategies. Irina Cleemput, PhD, senior health economist, explains, “The panel reached consensus on the importance of public and patient involvement in health care coverage decisions, however, they see different roles for patients and citizens. While citizens should be involved in determining the general priorities in health care, patients should be involved in coverage decisions as experts by experience.” The full study, “Acceptability and Perceived Benefits and Risks of Public and Patient Involvement in Health Care Policy: A Delphi Survey in Belgian Stakeholders,” is published in Value in Health.

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×